Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seasonal influenza virus vaccine intranasal - BioDiem

Drug Profile

Seasonal influenza virus vaccine intranasal - BioDiem

Alternative Names: Influenza vaccine live attenuated - BioDiem; Influenza virus vaccine - BioDiem; Influenza virus vaccine - Serum Institute of India; Influenza virus vaccine live - BioDiem; Influenza virus vaccine live intranasal - BioDiem; LAIV Seasonal intranasal - BioDiem; Live attenuated influenza vaccine - BioDiem; Live attenuated influenza virus vaccine - BioDiem; Nasovac-S; SCH-900795; Seasonal influenza virus vaccine (intranasal) - BioDiem; Seasonal influenza virus vaccine - BioDiem; Trivalent live attenuated seasonal influenza vaccine - Serum Institute of India; Trivalent seasonal influenza virus vaccine - Serum Institute of India/Biodiem

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer BioDiem; Changchun BCHT Biotechnology; Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Class Attenuated vaccines; Influenza virus vaccines live; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 17 Mar 2022 Changchun BCHT Biotechnology plans a phase II trial for Influenza virus infections (Prevention, In children, In adolescents, In adults) in China, in April 2022 (Intranasal) (NCT05284851)
  • 06 Oct 2021 Changchun BCHT Biotechnology submitted a new drug application (NDA) for Influenza virus infections in 2021 (NCT05056519)
  • 19 Feb 2021 BioDiem intends to launch Seasonal influenza virus vaccine intranasal in year 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top